Financial Performance - Shenzhen Neptunus Interlong Bio-technique Company Limited reported a revenue of RMB 500 million for the fiscal year 2021, representing a 15% increase compared to the previous year[14]. - The company achieved a net profit of RMB 80 million, which is a 20% increase year-on-year, indicating strong operational performance[14]. - The Group's total revenue for the Year was approximately RMB 838,805,000, representing a decrease of approximately 18.67% compared to the previous year[69]. - Revenue from the manufacturing and selling of medicines segment was approximately RMB 510,221,000, accounting for approximately 60.83% of total revenue, with a year-on-year increase of approximately 15.62%[69]. - Revenue from the sales and distribution of medicines and healthcare products segment was approximately RMB 328,584,000, accounting for approximately 39.17% of total revenue, with a year-on-year decrease of approximately 44.32%[69]. - The gross profit for the Year was approximately RMB 374,103,000, representing a decrease of approximately 34.87% from RMB 574,360,000 in the previous year[71]. - The gross profit margin decreased to approximately 45% from 56% in the previous year, a decline of about 11 percentage points[74]. - Profit after tax decreased to approximately RMB 34,306,000, down approximately 11.45% from RMB 38,742,000 in the previous year[79]. Market Expansion and Strategy - User data showed a growth in active users by 25%, reaching a total of 1.5 million active users by the end of 2021[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[14]. - A strategic acquisition of a local biotech firm is anticipated to enhance the company's product portfolio and is expected to be completed by Q3 2022[14]. - The Group is expanding its product line and adopting a diversified development strategy to stabilize business and maintain growth in the face of market competition[54]. - The Group aims to enhance product quality and core competitiveness through the development of traditional Chinese medicine[31]. - The Group's strategy includes diversifying development, enhancing regional market development, and launching promotional activities to stabilize business growth[55]. Research and Development - The company has allocated RMB 20 million for research and development in new technologies, focusing on enhancing product efficacy and safety[14]. - The Group's research and development efforts focus on quality consistency evaluation and new varieties of medicines[30]. - The Group plans to allocate more resources to research and development of new drugs and improve production capacity and product quality assurance systems[64]. - The Group aims to cultivate core varieties that are competitive in terms of efficacy, brand, or cost to ensure sustainable development[66]. Operational Efficiency - The company aims to improve operational efficiency by reducing production costs by 10% through process optimization[14]. - The Group's pharmaceutical subsidiaries have faced increased operational stress due to stricter national regulations and rising prices of Chinese medicinal materials, leading to higher manufacturing costs[43]. - To address these challenges, the subsidiaries have developed direct cooperation with active ingredient manufacturers and adjusted production plans to meet market demand, resulting in higher sales of high-margin products[43]. Corporate Governance and Management - The company is focused on expanding its market presence and enhancing its product offerings through strategic R&D initiatives led by experienced directors[123][127]. - The board of directors includes members with significant expertise in finance, management, and pharmaceutical research, ensuring robust governance and strategic oversight[127][133]. - The Company is committed to maintaining high standards of corporate governance through the involvement of independent directors in key committees[133]. - Future strategies may include potential mergers and acquisitions to enhance market share and product development capabilities[123][128]. Legal and Compliance - A lawsuit involving Fuzhou Neptunus Fuyao Pharmaceutical Company claimed approximately RMB 153.27 million, which has since been settled[49]. - The Group faced a legal dispute involving a claim of RMB 153,270,800, which was settled in January 2022, incurring related costs of approximately RMB 840,000[62]. - The Company received annual confirmations of independence from its independent non-executive Directors, maintaining compliance with GEM Listing Rules[173]. Employee and Staffing - As of December 31, 2021, the Group employed a total of 1,401 staff, an increase of 236 employees compared to 1,217 in 2020 due to the acquisition of Neptunus Zhongxin[107][109]. - Staff costs, including directors' remuneration, amounted to approximately RMB 120,083,000, up from approximately RMB 99,351,000 in 2020, reflecting a significant increase in employee compensation and benefits[108]. - The increase in employee numbers and costs is part of the Group's strategy to maintain competitiveness and broaden appeal[109]. - The Group provided various benefits and training opportunities to employees to enhance performance and retention[108][109]. Financial Position - Net current assets as of December 31, 2021, were approximately RMB 404,489,000, a decrease of approximately RMB 192,595,000 from RMB 597,084,000 as of December 31, 2020[87]. - The gearing ratio as of December 31, 2021, was approximately 38.46%, compared to nil in the previous year[90]. - The Group had short-term bank borrowings of RMB 101,137,000 as of December 31, 2021[84]. - The Group has contracted commitments for future capital expenditure of approximately RMB 1,337,000, which is expected to be financed by bank deposits and borrowings[104]. Shareholder Information - The Company did not recommend any dividends for the Year, consistent with the previous year where no dividends were distributed[158]. - As of December 31, 2021, the Company had no distributable reserves, with accumulated losses amounting to approximately RMB 1.2 billion[158]. - The substantial shareholders' interests in shares or underlying shares were recorded in the register required to be kept by the Company[200].
海王英特龙(08329) - 2021 - 年度财报